|Mr. David Fellows||CEO & Director||N/A||N/A||1957|
|Mr. Senthil Sundaram||Chief Financial Officer||N/A||N/A||1978|
|Dr. Gregory Robinson||Chief Scientific Officer||N/A||N/A||1959|
|Brian Luque||Sr. Mang. of Investor Relations||N/A||N/A||N/A|
|Mr. Bryan Yoon||Gen. Counsel & Sec.||N/A||N/A||1978|
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.
Nightstar Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.